Please login to the form below

Not currently logged in
Email:
Password:

Servier

This page shows the latest Servier news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

CTI slumps as Servier-partnered lymphoma drug fails

CTI slumps as Servier-partnered lymphoma drug fails. After major setback CTI, has promising myelofibrosis candidate to fall back on. ... It’s also a knock for privately-held French drugmaker Servier in all markets outside the US under the terms of a

Latest news

More from news
Approximately 18 fully matching, plus 94 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    The Xoma licensing deal is interesting because it required Novartis to settle the $14m debt owed to Xoma’s previous licensee Servier.

  • Deal Watch March 2017 Deal Watch March 2017

    name. (Abexinostat was formerly in development by Pharmacyclics (now owned by AbbVie) and Servier.) Both ACAT-1 (for which Xynomic paid $1.2m upfront with another $59m in potential milestones) and

  • Deal Watch January 2017 Deal Watch January 2017

    What goes around, comes around The appetite for immuno-oncology (IO) has survived well into 2017 with Servier closing the biggest IO headline deal in January with Pieris for $1.7bn ... 3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside

  • Deal Watch July 2016 Deal Watch July 2016

    At the other end of the development spectrum Servier paid the same amount upfront for the rights to Sorrento's immuno-oncology product: STI-A1110, an anti-PD-1 mAb, presently ... Licence. 1, 115. Sorrento Therapeutics/ Servier. STI-A1110 - anti-PD1

  • Searching for health Searching for health

    The 27 hectare site, with two production plants making pharmaceuticals and cosmetics, is a crucial springboard for new therapies and the industry-wide commitment to rebuild after Servier's appetite suppressant

More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics